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SchizophreniaSchizophrenia (SCZ) is a common complex disorder with poorly understood mechanisms and no effective
drug treatments. Despite the high prevalence and vast unmet medical need represented by the disease,
many drug companies have moved away from the development of drugs for SCZ. Therefore, alternative
strategies are needed for the discovery of truly innovative drug treatments for SCZ. Here, we present a
disease phenome-driven computational drug repositioning approach for SCZ. We developed a novel drug
repositioning system, PhenoPredict, by inferring drug treatments for SCZ from diseases that are pheno-
typically related to SCZ. The key to PhenoPredict is the availability of a comprehensive drug treatment
knowledge base that we recently constructed. PhenoPredict retrieved all 18 FDA-approved SCZ drugs
and ranked them highly (recall = 1.0, and average ranking of 8.49%). When compared to PREDICT, one
of the most comprehensive drug repositioning systems currently available, in novel predictions,
PhenoPredict represented clear improvements over PREDICT in Precision-Recall (PR) curves, with a sig-
niﬁcant 98.8% improvement in the area under curve (AUC) of the PR curves. In addition, we discovered
many drug candidates with mechanisms of action fundamentally different from traditional antipsy-
chotics, some of which had published literature evidence indicating their treatment beneﬁts in SCZ
patients. In summary, although the fundamental pathophysiological mechanisms of SCZ remain
unknown, integrated systems approaches to studying phenotypic connections among diseases may
facilitate the discovery of innovative SCZ drugs.
 2015 Elsevier Inc. All rights reserved.1. Introduction
Mental illness causes enormous personal and societal burdens
[1]. In fact, mental illnesses, such as schizophrenia (SCZ), bipolar
disease, depression and other psychiatric disorders, is the leading
cause of impairment and disability in the United States and
world-wide, accounting for around one-third of the disabilities in
the world [2,3]. SCZ is arguably the most intractable among all psy-
chiatric disorders [4]. SCZ has a life-time prevalence of 1%, typically
beginning before age 25 years and persisting throughout the life of
the individual [3]. Currently, effective drugs do not exist for treat-
ing SCZ [5]. Despite the vast unmet medical need, many drug com-
panies have moved away from SCZ drug development, in part
because of the high costs, high failure rates in clinical trials,
lengthy development processes, and a poor understanding of
underlying mechanisms of the disease [5–7].
In this study, we present a computational drug repositioning
approach towards discovering innovative drug candidates for thetreatment of SCZ. Psychiatric drug discovery has traditionally come
from repositioning existing drugs based on serendipitous clinical
observations [8]. For example, lithium, originally approved as a
sedating agent, is now used in the treatment of mania [9].
Chlorpromazine, originally approved as an antihistamine, is now
used in the treatment of schizophrenia [10]. Iproniazid, originally
approved as an anti-tuberculosis agent, is now used in the
treatment of depression [11]. Ketamine, originally approved as an
anesthetic agent, has rapid antidepressant effects in patients
with major depression [12]. Computation-based repositioning
approaches that automatically reason over vast amounts of
genetic, genomic, chemical, and phenotypic data can greatly speed
up the timeline of traditional serendipity-based psychiatric drug
discovery process and facilitate the identiﬁcation of truly innova-
tive drug treatments for SCZ and other psychiatric disorders
[13–15]. However, computational drug repositioning approaches
for identifying novel drug candidates for SCZ has not been fully
explored.
Computational drug repositioning approaches can be classiﬁed
as either drug-based or disease-based [14,15]. Drug-based
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functions of drugs, such as chemical structures and properties,
molecular docking, gene expression, drug treatment indications,
and drug side effects [16–24]. In the past 50 years, psychiatric drug
discovery has been largely drug-based and has focused on identify-
ing molecules with which existing drugs interact. Consequently, all
current antidepressants, antipsychotics, and anti-anxiety drugs
developed and marketed from the 1950s to the current day have
targeted the same molecular pathways in the brain as their proto-
types [5]. it has been recognized that drug-based discovery, with
its focus on ﬁnding drug candidates based on existing drugs, might
by deﬁnition fail to identify new therapeutic mechanisms [25]. An
alternative approach is disease-based discovery, which puts less
emphasis on existing drugs and focuses more on disease mecha-
nisms and interrelationships. Because disease-based approaches
look for similarities and interrelationships among diseases, these
approaches are able to identify innovative drugs. Compared to
drug-based repositioning approaches, disease-based approaches
are surprisingly less explored and mainly used disease gene
expression data [19,20].
We hypothesize that higher-level phenotypic overlaps among
diseases reﬂect underlying biological commonalities and that
insights from one disease may be used to inform our developing
knowledge of others. We developed a phenotype-driven drug repo-
sitioning system, PhenoPredict, to exploit drug repositioning
opportunities rendered by disease phenotype data captured in
the Human Phenotype Ontology (HPO) and a comprehensive
drug-disease treatment relationship knowledge base (TreatKB)
that we recently constructed [26–28]. HPO is a standardized
vocabulary of phenotypic abnormalities encountered in human
disease [29]. HPO contains phenotypic descriptions of 7529 dis-
eases, the majority of which were derived from the Online
Mendelian Inheritance in Man (OMIM) [30]. Studies of phenotypic
abnormalities in HPO have advanced our understanding of the
genetic bases of diseases [31–33]. In a recent study, Gottlieb
et al. used disease phenotypic similarities deﬁned in HPO and
drug-drug similarities from other databases to construct a
classiﬁer (PREDICT) and then used it to determine treatment
associations between 593 drugs and 313 diseases, including SCZ
[34]. Different from PREDICT, PhenoPredict used a network-based
approach to systematically exploit phenotypic interrelationships
among diseases as deﬁned in HPO. More importantly,Fig. 1. The overall experimentalPhenoPredict used a novel drug prioritization algorithm to exploit
treatment connections among diseases as deﬁned in TreatKB,
which is a key component of PhenoPredict. Compared to
PREDICT, our study included signiﬁcantly more drugs and diseases
(2482 drugs and 24,511 unique disease concepts). We compared
PhenoPredict to PREDICT in novel drug predictions using multiple
evaluation datasets and demonstrated that PhenoPredict achieved
consistently better performances.
2. Data and methods
The experiment framework for PhenoPredict is depicted in
Fig. 1 and consists of four phases: (1) We constructed a phenotypic
disease network (PDN) using disease-disease similarity measures
from HPO. We then developed a network-based ranking algorithm
to ﬁnd diseases that are phenotypically related to SCZ; (2) In order
to validate the network construction and ranking algorithms of
PhenoPredict and to better understand SCZ-related diseases, we
analyzed disease class distributions among diseases at different
ranking cutoffs and investigated what kinds of diseases were
enriched among top-ranked SCZ-related diseases; (3) We
developed a novel drug repositioning algorithm to systematically
identify drug repositioning candidates from SCZ-related diseases.
We evaluated PhenoPredict using FDA-approved SCZ drugs. We
compared PhenoPredict to PREDICT in novel predictions; and
(4) In order to better understand top-ranked drug candidates, we
examined drug class distributions among both top- and
intermediate-ranked drug candidates.
2.1. Construct the phenotypic disease network (PDN) and ﬁnd
SCZ-related diseases from PDN
2.1.1. Construct phenotypic disease network (PDN)
PDN was constructed by directly using the disease-disease
similarity matrix obtained from HPO. In HPO, individual diseases
are often associated with multiple phenotypic terms. Similarity
measures for any two given phenotypic terms were calculated
based upon shared information content (frequency among annota-
tions of all diseases) in the set of their common-ancestor nodes.
The similarity between two diseases was then calculated by
matching each phenotypic term of one disease with the most sim-
ilar term of the other disease; the average was taken over all pairsﬂow chart for PhenoPredict.
Table 1
Sixteen disease chapters (classes) and the number of diseases (synonym expanded) in each chapter.
Disease class Diseases (n) Disease classes Diseases (n)
Certain infectious and parasitic diseases 11,598 Diseases of the circulatory system 5544
Neoplasms 14,158 Diseases of the respiratory system 3156
Diseases of the blood and blood-forming organs
and certain disorders involving the immune mechanism
3264 Diseases of the digestive system 5960
Endocrine, nutritional and metabolic diseases 5438 Diseases of the skin and subcutaneous tissue 4390
Mental and behavioural disorders 6162 Diseases of the musculoskeletal system and connective tissue 11,520
Diseases of the nervous system 5258 Diseases of the genitourinary system 5247
Diseases of the eye and adnexa 3735 Congenital malformations, deformations and chromosomal abnormalities 9064
Diseases of the ear and mastoid process 1815 Certain conditions originating in the perinatal period 3454
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similarity matrix and mapped disease terms to the Uniﬁed Medical
Language System (UMLS) [35] Concept Unique Identiﬁers (CUIs) in
order to facilitate the subsequent linking to drug-disease treat-
ment pairs in TreatKBs that were constructed from other data
sources. A total of 5708 out of 7529 disease terms in HPO were
mapped to UMLS CUIs. Instead of excluding unmapped terms, we
used the term names as their unique identiﬁers. In total, we
obtained 17,523,509 disease-disease pairs, representing 7210
unique disease concepts. The similarity scores from the matrix
were used as the edge weights of PDN. We also generated ten ran-
dom PDNs by randomly shufﬂing edges of the real PDN.
2.1.2. Develop network-based ranking algorithm for ﬁnding SCZ-
related diseases
Recently, we developed network-based approaches to prioritize
genes for a given disease [36] and to prioritize diseases for a given
microbial metabolite [37]. In this study, we applied these
network-based algorithms to prioritize diseases for SCZ. The itera-
tive network-based ranking algorithm is deﬁned as:
ptþ1 ¼ ð1 rÞMpt þ rp0, wherein M is the column-normalized adja-
cency matrix of PDN, c is a preset probability of restarting from the
initial seed node (c ¼ 0:1 in this study), and pt is a vector in which
the ith element holds the normalized ranking score of disease i at tth
iteration. The initial probability vector p0 contains normalized
probability values for input. In our study, p0 contains SCZ, with a
probability of 1.0. Diseases are ranked according to values in the
steady-state probability vector, which is obtained by iterating the
algorithm until the change between ptþ1 and pt is less than 106.
2.2. Analyze disease class distribution at different ranking cutoffs
To better understand ranked diseases, we analyzed disease class
distribution at ten different ranking cutoffs. Using SCZ as the seed,
we retrieved a ranked list of 7204 diseases from PDN. We classiﬁed
these diseases into sixteen categories using the 10th revision of the
International Statistical Classiﬁcation of Diseases and Related
Health Problems (ICD10), a disease classiﬁcation scheme desig-
nated by the World Health Organization (WHO) [38]. The ICD10
includes 22 highest-level disease classes (or chapters) such as
‘‘Neoplasms’’ and ‘‘Diseases of the nervous system’’. We used six-
teen chapters and excluded the other six non-speciﬁc disease
classes such as ‘‘Codes for special purposes’’ and ‘‘Injury, poisoning
and certain other consequences of external causes’’. Because the
terms used in ICD10 may differ from those in PDN, we expanded
disease terms in ICD10 to their synonyms through UMLS CUIs.
Disease chapters and the numbers of diseases in each chapter are
listed in Table 1.
At ten ranking cutoffs (10%, 20%, . . . , 100%), we calculated per-
centages of these sixteen disease classes among retrieved diseases.
For example, at the 100% cut-off (all 7204 retrieved diseases),
3.89% of the diseases were classiﬁed as ‘‘Mental, behavioural disor-
ders’’. At the 10% cutoff (top 720 diseases), 87 out of the 720diseases (12.05%) were classiﬁed as ‘‘Mental, behavioural disor-
ders,’’ representing a 209.8% increase as compared to the 100% cut-
off ((12.05–3.89)/3.89 = 209.8%). This means that top-ranked
diseases on average includedmore ‘‘Mental, behavioural disorders’’
than lower-ranked diseases. While this was expected and demon-
strates the validity of the disease ranking algorithm, we found that
certain other disease classes such as ‘‘Endocrine, nutritional and
metabolic diseases’’ were enriched among top-ranked diseases.2.3. Reposition drugs
2.3.1. Drug repositioning algorithm
We developed an approach to systematically identify drug
repositioning candidates from SCZ-related diseases. We ranked
drugs based on the number of SCZ-related diseases that they are
currently approved to treat as well as the ranking scores of these
diseases. For example, if drug 1 treats 25 top-ranked diseases, it
would be ranked higher than drug 2, which treats only one or
two lower-ranked diseases. The drug ranking algorithm is deﬁned
as: Rdrug ¼
Pn
i¼1R disease i, wherein n is the number of SCZ-related
diseases that are currently approved to treat and R disease i is the
disease ranking score (output from the network-based disease
ranking algorithm). During the experiment, we found that certain
drugs were consistently ranked highly for both the real PDN and
random PDNs. For example, the drug ‘‘chlordiazepoxide’’ was
ranked at top 0.32% for the real PDN and on average at top 0.36%
for andom PDNs. We designed our reprioritization strategy by
accounting for rankings of a drug for random PDNs. A drug was
ranked highly if and only if it was ranked highly based on the real
PDN and the ratio of its ranking for the real PDN to that for random
PDNs is at least 2-fold.2.3.2. Comparison of four TreatKBs in a de novo validation setting
using 18 known SCZ drugs as evaluation dataset
In order to systematically reposition drug treatments from one
disease to another, it is critical to have a comprehensive drug treat-
ment knowledge base. In our recent studies, we constructed four
large-scale drug-disease treatment knowledge bases (TreatKBs)
from multiple heterogeneous and complementary data sources
using advanced computational techniques including natural lan-
guage processing, text mining, and data mining [26–28]. The data-
bases included 9216 drug-disease treatment pairs extracted from
FDA drug labels, 111,862 pairs extracted from the FDA Adverse
Event Reporting System (FAERS), a database supporting the FDA’s
post-marketing drug safety surveillance efforts, 34,306 pairs
extracted from 22 million published biomedical literature
abstracts, and 69,724 pairs extracted from 171,805 clinical trials.
The combined TreatKB consists of 208,330 unique drug-disease
treatment pairs, representing 2484 drugs and 24,511 unique dis-
ease concepts.
We evaluated PhenoPredict using all 18 FDA-approved SCZ
drugs by comparing its performance across four TreatKBs. Since
SCZ and its associated drug treatment pairs were removed from
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drug-disease treatment pairs), the evaluation is in fact a de novo
validation. We calculated the rankings of the 18 FDA-approved
SCZ drugs among all retrieved drugs and used them as our gold
standard. We assumed that the higher these gold standard drugs
were ranked, the better the ranking algorithm was. We compared
the performances (recall and average rankings) across four
TreatKBs separately and in combination.Fig. 2. Percentages of three disease classes among 7204 diseases retrieved from
HPON at ten ranking cutoffs (top 10%, 20%, . . . , 100% (all diseases)). For example,
ranked diseases at top 10% cutoff (top 720 diseases) contain 12.05% diseases from
the class ‘‘Mental, behavioural disorders’’. Thirteen unenriched disease classes are
not shown.2.3.3. Compare PhenoPredict to PREDICT in novel predictions
We compared PhenoPredict to PREDICT in novel predictions
using three evaluation datasets: (1) 195 drugs that had been tested
in SCZ clinical trials; (2) 50 drugs that were in ongoing SCZ clinical
trials initiated in 2012 and after. These drugs may represent newer
SCZ drugs; and (3) 114 drugs that the literature implies have been
used to treat varying symptoms of SCZ. These three evaluation
datasets were derived from TreatKBs, which was constructed from
multiple data resources including 22 million published biomedical
literature abstracts and 171,805 clinical trials [26–28]. The 18
FDA-approved drugs were removed from these three evaluation
datasets. Note that all SCZ-related drug treatment information
were removed from TreatKB before PhenoPredict made predictions
for SCZ.
We used Precision-Recall (PR) curves instead of Receiver
Operator Characteristic (ROC) curves to evaluate and compare
PhenoPredict to PREDICT. PR curves are often used to evaluate
ranked classiﬁcation results in information retrieval [39]. ROC
curves are commonly used to evaluate binary classiﬁcation prob-
lems in machine learning and data mining [40]. A PR space is
deﬁned as precision (fraction of examples classiﬁed as positive that
are truly positive) and recall (true positive rate) as x and y axes,
respectively. An ROC space is deﬁned by FPR (false positive rate)
and TPR (the same as recall) as x and y axes, respectively. Studies
have shown that in domains where the number of negatives
greatly exceeds the number of positives, such as in drug reposition-
ing and most other biomedical classiﬁcation domains, ROC curves
can present an overly optimistic view of an algorithm’s perfor-
mance as compared to PR curves [41,42]. Davis et al. proved that
a curve dominates in ROC space if and only if it dominates in PR
space and algorithms that optimize the ROC curve are not guaran-
teed to optimize the PR curve [42]. Therefore, in our study, we used
PR curves even though most biomedical classiﬁcation studies use
ROC curves.
PREDICT utilizes multiple drug-drug and disease-disease simi-
larity measures for the prediction task [34]. PREDICT ﬁrst trains a
logistic regression classiﬁer using known drug-disease associa-
tions. It then classiﬁes additional drug-disease associations based
on their similarity to the known associations. We compared
PhenoPredict to PREDICT in novel predictions. A total of 593 drugs
were included in PREDICT, among which 79 drugs were classiﬁed
as positives for SCZ. The 79 drugs along with their corresponding
probabilities (ranging from 0.543 to 0.994) are publicly available
[34]. The remaining 524 drugs were predicted by PREDICT as neg-
atives for treating SCZ. We assigned each negative prediction a
value that was randomly picked from 0.0 to 0.499. We repeated
this process of assigning values to negatives for ten iterations
and generated ten datasets for PREDICT. PR curves for these ten
datasets were similar, therefore we did not generate more datasets
for PREDICT. The PR curves for PREDICT were then averaged across
the ten datasets that we generated. The output from PhenoPredict
is a ranked list of 2484 drugs. Using each of the three evaluation
datasets as gold standard, we calculated precisions at 10 different
recall cutoffs (0.1, 0.2, . . . , 1.0) for both PhenoPredict and PREDICT
and plotted the PR curves. The area under curves (AUC) was used to
compare the two approaches.2.4. Analyze repositioned drug candidates
It is important to the current study, as well as to future work in
the ﬁelds of computational drug repositioning, to better under-
stand the nature of identiﬁed drug repositioning candidates. In
order to facilitate such an understanding, we examined the class
distributions of drug repositioning candidates. Drug classes were
deﬁned by the Anatomical Therapeutic Chemical (ATC) classiﬁca-
tion system [43]. The ATC system consists of 13 ﬁrst-level codes,
94 s-level codes, 267 third-level codes, 882 fourth-level codes,
and 4580 ﬁfth-level codes. The ﬁfth-level codes are individual
drugs. In our study, we used the third level ATC codes for the anal-
ysis. We examined top ranked drug classes for drug candidates
ranked in the range of top 0–15% and in the range of top16–30%
separately.3. Results
3.1. Disease class analysis
Using SCZ as the seed, we retrieved a ranked list of 7204 dis-
eases from PDN. We calculated percentages of sixteen disease
classes among these retrieved diseases at ten different ranking cut-
offs (10%, 20%, . . . , 100%). Among the sixteen disease classes, three
disease classes were enriched among top-ranked diseases:
‘‘Mental, behavioural disorders’’, ‘‘Diseases of the nervous system’’,
and ‘‘Endocrine, nutritional and metabolic diseases’’ (Fig. 2). The
increase for the disease class ‘‘Mental, behavioural disorders’’
was particularly pronounced, with a 209.8% increase for the top
10% diseases as compared to all retrieved diseases. The increases
for the other two classes are similar but less prominent. In sum-
mary, the enrichment of ‘‘Mental, behavioural disorders’’, to which
SCZ belongs, among top-ranked diseases, demonstrated the valid-
ity of our phenotype-driven network-based disease ranking
algorithm.3.2. FDA-approved SCZ drugs were ranked highly
When the TreatKB containing only FDA-approved drug-disease
treatments was used, PhenoPredict achieved a recall of 0.33 and
an average ranking of 30.9%. When the other three TreatKBs were
Table 2
Comparing recalls and average rankings of 18 FDA-approved SCZ drugs for four
TreatKBs individually and combined.
TreatKB Recall Average ranking (%)
FDA-approved 0.33 30.9
Post-market 1.00 10.48
ClinicalTrials 0.67 21.65
Literature 0.83 10.97
Combined 1.00 8.49
Fig. 3. Precision-Recall curves for PhenoPredict and PREDICT using 195 drugs from
SCZ clinical trials as gold standard.
Fig. 4. Precision-Recall curves for PhenoPredict and PREDICT using 50 drugs from
ongoing SCZ clinical trials as gold standard.
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terms of both recalls and rankings (Table 2). Signiﬁcantly, when
all fourTreatKB were combined, PhenoPredict achieved a recall of
1.00 and an average ranking of 8.49%. These results demonstrate
that a comprehensive TreatKB is critical component of
PhenoPredict.
3.3. PhenoPredict performed better than PREDICT in novel predictions
We plotted PR curves for PhenoPredict and PREDICT using the
195 drugs extracted from SCZ clinical trials as the evaluation set.
The PR curve for PhenoPredict clearly dominates that for
PREDICT. The area under the curve (AUC) for PhenoPredict is
0.489, representing a 98.8% improvement as compared to the
AUC of 0.246 for PREDICT (Fig. 3).
When evaluated with 50 drugs extracted from ongoing SCZ clin-
ical trials, PhenoPredic achieved an AUC of 0.128, representing an
81.1% improvement as compared to the AUC of 0.071 for
PREDICT (Fig. 4).
The PR curves determined using the 114 drugs that the litera-
ture implies have been used to treat varying symptoms of SCZ as
the evaluation set are shown in Fig. 5. PhenoPredict achieved of
an AUC of 0.289, representing a 41.2% improvement as compared
to the AUC of 0.208 for PREDICT. In summary, PhenoPredict consis-
tently showed improved PR curves compared to those for PREDICT
across three different evaluation datasets.
Table 3 shows the top 20 repositioned drug candidates, all of
which are implicated as promising candidates through evidence
from sources other than our experiment, such as FDA drug labels,
clinical trials, or biomedical literature. Among these 20 drugs, 8
are FDA-approved drugs. These speciﬁc examples further demon-
strate the potential of PhenoPredict in identifying promising drug
repositioning candidates for SCZ.
3.4. Analysis of repositioned drug candidates offers insights to common
mechanisms of action
The top drug candidates, those ranked in the 0–15% range, were
associated with a total of 95 third-level ATC codes. Fig. 6 shows the
top 15 drug classes, among which 13 classes are related to antipsy-
chotics, including antidepressants, antiepileptics, and dopaminer-
gic agents. We have shown in the disease class analysis that
mental diseases were highly enriched among top-ranked diseases;
therefore, it is not surprising that most of the top ranked drug can-
didates are typical antipsychotics. This result also demonstrates
that common pathophysiologic mechanisms are shared among
phenotypically related psychiatric disorders and that traditional
psychiatric drug discovery may have fully exploited this common-
ality (i.g. the same drugs are used among related diseases).
While top ranked drugs are mainly antipsychotics, drugs with
intermediate rankings may provide opportunities for discovering
innovative drugs. Fig. 7 shows the top 15 drug ATC codes for drugs
ranked in the range of 16–30%. The majority of these top ATC codes
are not related to antipsychotics. Evidence gleaned from the pub-
lished biomedical literature shows that these drug classes mayhave treatment potential in SCZ patients. For example, two ATC
codes ‘‘immunodepressants’’ and ‘‘antiinﬂammatory and
antirheumatic’’ were ranked highly. Studies have shown that
immune dysfunction and inﬂammation are involved in patients
with SCZ [44,45]. Therefore, anti-inﬂammatory drugs may repre-
sent promising treatments for SCZ. In a randomized controlled
study, celecoxib, a widely used anti-inﬂammatory agent, was
shown to improve symptoms experienced by SCZ patients without
major side effects [46]. Recent genetic ﬁndings from genome-wide
association studies (GWAS) also point to possible common
genetic connections between SCZ and immune disorders [47].
Beta-blockers were also ranked highly. Beta blockers are com-
monly used to treat hypertension and cardiovascular diseases.
Studies have shown that they may reduce anxiety and extrapyra-
midal symptoms in SCZ and have been suggested as adjunctive
therapies to antipsychotics in SCZ or similar severe mental
disorders [48,49]. The output of PhenoPredict also suggests the
potential use of angiotensin antagonists as an atypical SCZ
treatment. Angiotensin antagonists are primarily used in the treat-
ment of hypertension, congestive heart failure, and heart attacks.
Fig. 5. Precision-Recall curves for PhenoPredict and PREDICT using 114 drugs
extracted from biomedical literature (MEDLINE) as gold standard.
Table 3
Top 20-ranked repositioned drug candidates. NCT⁄⁄: SCZ drugs from clinical trials. PMID⁄⁄
R Drug Evidence R Drug
1 Risperidone FDA-approved 11 Mema
2 Methylphenidate NCT00794040 12 Buspir
3 Quetiapine FDA-approved 13 Palipe
4 Citalopram NCT00893256 NCT00047450 NCT01032083
NCT01032083
14 Halop
5 Olanzapine FDA-approved 15 Lithium
6 Sertraline NCT00169988, NCT00531518 16 Aman
7 Aripiprazole FDA-approved 17 Levod
8 Ziprasidone FDA-approved 18 Atomo
9 Clozapine FDA-approved 19 Clomi
10 Valproic acid NCT00194025 NCT01094249 NCT02011750 20 Predni
Fig. 6. Top 15 third level ATC codes (out of 95 codes) and their percentages for drug cand
of 0–15% belong to the class ‘‘antidepressants’’.
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nervous system activity [50,51]. Neurochemical and anecdotal
reports suggest that angiotensin antagonists may have
mood-elevating and cognitive enhancing functions in patients,
however mechanisms of actions by which these inhibitors modify
cognitive performance remain unknown [52].4. Discussion
We developed a drug repositioning system, PhenoPredict, to
exploit the phenotypic connections among diseases and applied
it to identify drug repositioning candidates for the treatment of
SCZ. PhenoPredict ranked many traditional antipsychotic drugs
highly, demonstrating the validity of the algorithms. In addition,
we discovered many drug repositioning candidates with mecha-
nisms of action fundamentally different from traditional antipsy-
chotics, each of which has substantial literature-based evidence
implicating its potential beneﬁts in the treatment of SCZ patients.
However, PR curves for PhenoPredict are not optimal and can cer-
tainly be improved upon with future research efforts.: SCZ drugs from biomedical literature. The FDA-approved SCZ drugs are highlighted.
Evidence
ntine NCT02001103 NCT00757978 NCT00097942
one NCT00178971
ridone FDA-approved
eridol FDA-approved
NCT00202306 NCT00183443 NCT00202293
tadine NCT00999505 NCT00975611 NCT00401973
opa NCT01636037
xetine NCT00420498 NCT00222794 NCT00488163 NCT00628394
NCT00161031, NCT00089869
pramine PMID9659874 PMID7635998 PMID7903293
sone PMID17245324 PMID23738211
idates ranked in the range of 0–15%. For example, 9.94% of drugs ranked in the range
Fig. 7. Top 15 third level ATC codes (out of 93 codes) and their percentages for repositioned drug candidates ranked in the range of 16–30%. For example, 3.31% of drugs
ranked in the range of 16–30% belong to the class ‘‘immunosuppressants.’’
354 R. Xu, Q. Wang / Journal of Biomedical Informatics 56 (2015) 348–355First, it will be interesting to test the generalizability of
PhenoPredict for other diseases. Currently, PhenoPredict included
drug-disease treatment relationships for a total of 24,511 diseases
and 2484 drugs. In theory, PhenoPredict can rank the 2484 drugs
for each of the 24,511 diseases or vice versa.
Second, it will be interesting to investigate why PhenoPredict
outperformed PREDICT. Such knowledge can offer insight into
how to further improve both systems. Since the algorithms as well
as the datasets included in both PhenoPredict and PREDICT are
integral parts of these two systems, it is unclear which (algorithms
or datasets or both) contributed to the PhenoPredict’s advantage
over PREDICT in ﬁnding drug candidates for schizophrenia. It will
be interesting to investigate whether integrating datasets from
both PhenoPredict and PREDICT can further improve the perfor-
mances for each system.
Third, a limitation of using disease phenotypes in HPO for drug
repositioning is that HPO mainly includes rare Mendelian disor-
ders, the majority of which themselves have no available drug
treatments. Therefore, the success of PhenoPredict in identifying
drug repositioning candidates from similar diseases to a given
input disease largely depends on the input disease as well as the
treatment availability for top-ranked diseases.
Fourth, disease genetics and genomics, in combination with dis-
ease phenotypes, may further facilitate the discovery of truly inno-
vative drug candidates for SCZ. Psychiatric disorders are among the
most heritable of all common complex diseases. Human genomics
and genetics studies have recently identiﬁed a large number of
genetic risk factors for psychiatric disorders [47]. Although nearly
all of the identiﬁed SCZ loci are nonspeciﬁc and not fully penetrant,
recent GWAS studies have demonstrated shared genetic loci
among phenotypically related psychiatric disorders including SCZ
and bipolar disorder. While this justiﬁes our approach of using dis-
ease phenotype data for drug repositioning, disease genetics and
genomics may provide additional information not captured by dis-
ease phenotypes. However, the task of how to combining different
level of evidence, including genetics, genomics, and phenomics, in
order to build compassing predictive models for drug repositioning
is challenging. We are actively exploring options for how to best
accomplish this task.Last but not least, incorporating other types of
disease-phenotype relationships such as disease comorbidities
and disease risk factors may offer additional drug repositioning
opportunities for SCZ. Recently, we constructed three large-scale
disease phenotypic knowledge bases, including a disease comor-
bidity knowledge base, a disease-risk relationship knowledge base,
and a disease-manifestation knowledge base [27,53,54]. Unlike
HPO, which includes exclusively Mendelian genetic disorders,
these disease phenotype knowledge bases contain not only
Mendelian disorders but also many common complex diseases.
Currently, we are developing approaches to integrate disease phe-
notype knowledge from these complementary and heterogeneous
data resources in an effort to further improve PhenoPredict.Funding
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